Atossa Therapeutics (ATOS) vs Pasithea Therapeutics (KTTA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pasithea Therapeutics (KTTA) has outperformed Atossa Therapeutics (ATOS) over the past year, gaining 63.9% versus a loss of 86.4%. Over five years, ATOS leads with a -95.3% price change compared with -99.4% for KTTA. Pasithea Therapeutics is the larger company by market cap ($17.6 million vs $15.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATOS | KTTA |
|---|---|---|
| Share price | $1.60 | $0.4787 |
| Market cap | $15.92M | $17.59M |
| 1-day change | -8.86% | -0.48% |
| YTD return | -81.98% | -62.89% |
| 1-year return | -86.37% | +63.94% |
| 5-year return | -95.34% | -99.40% |
| EPS (TTM) | $-3.92 | $-1.38 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-34.77M | $-20.43M |
| 52-week high | $14.85 | $2.06 |
| 52-week low | $1.59 | $0.32 |
| Distance from 52-week high | -89.26% | -76.76% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1091.22% | +526.70% |
| Average volume | 68.00K | 705.64K |
| Shares outstanding | 9.98M | 36.75M |
| Employees | 16 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KTTA has outperformed ATOS by 150.3 percentage points over the past year.
About Atossa Therapeutics
ATOS stock →Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in areas of significant unmet medical need in oncology in the United States. Its lead drug candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and selective estrogen receptor degrader currently in Phase 2 clinical development for the treatment and reduction of risk of breast cancer, as well as in other therapeutic areas.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
About Pasithea Therapeutics
KTTA stock →Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
ATOS vs KTTA FAQ
Which is bigger, Atossa Therapeutics or Pasithea Therapeutics?
Pasithea Therapeutics (KTTA) is larger, with a market capitalization of $17.59M compared with $15.92M for Atossa Therapeutics (ATOS).
Which stock has performed better over the past year, ATOS or KTTA?
KTTA returned +63.94% over the past 12 months, compared with -86.37% for ATOS (price return, excluding dividends). Past performance does not predict future results.
Are Atossa Therapeutics and Pasithea Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.